×

To enhance security, Multi-Factor Authentication (MFA) is mandatory for all HL7 users. More information

 

FHIR Implementation Guide: Migrate from Structured Product Labeling V3 to a FHIR-based submission (PSS in Confluence)

Basics

FHIR Implementation Guide: Migrate from Structured Product Labeling V3 to a FHIR-based submission (PSS in Confluence)

1704
Ballot - STU to Normative


FHIR Implementation Guide

Implementation Guide

Details

IBM and FDA are partnering to produce a FHIR Implementation Guide that will allow stakeholders to migrate from the current Structured Product Labeling (SPL) V3 document architecture to a FHIR-based submission architecture. The Implementation Guide will provide profiles on FHIR resources as well as a mapping to and from the existing SPL V3 specification. Additionally, it will document an initial FHIR-based architecture for handling existing FDA SPL use cases in parallel with the current SPL-based architecture.

The initial scope will be focused on the pharmaceutical submissions along with the associated SPL use cases that are needed for those label submissions. As the project goes on, we will look at expanding beyond the pharmaceutical use case.

Since this is a US Realm project, we have analyzed US-Core and there is no overlap with the profiles and use cases covered by US-Core. Therefore there is no dependency on US-Core by this project.


The existing SPL submission process at FDA uses the existing V3 models. As part of a project that is looking at how the V3 submission could be enhanced or replaced with a FHIR-based submission, this Implementation Guide is needed to provide the guidance on how to use the FHIR artifacts.



Connectathon: Target - September 2021 Initial ballot: Target - January 2022 Publishing: Target - May 2022


https://confluence.hl7.org/display/BRR/FHIR+IG+Project+Space%3A+Migrate+from+SPL+V3+to+a+FHIR-based+submission PSS: https://confluence.hl7.org/display/BRR/FHIR+Implementation+Guide%3A+Migrate+from+Structured+Product+Labeling+V3+to+a+FHIR-based+submission



Regulatory Agency,Pharmaceutical

IBM FDA




Yes


No


Organization & Realm

Realm Specific - Enter "U.S." or name of HL7 Affiliate below

U.S.
People

Jean Duteau



Biomedical Research and Regulation Work Group


Status & Dates

Active

On Hold

11/24/2020

05/01/2028

2028 May WGM/Ballot

05/01/2027

2027 May WGM/Ballot

Approvals

04/26/2021


Received


All Received




System Info






09/17/2026

Anne Wizauer